Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection
© 2020 Wiley Periodicals LLC..
Treatment options for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta-analysis of studies on patients ≥18 years reporting data on therapeutic interventions in SARS-CoV-2. Primary outcome was all-cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge, and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty-nine studies with 5207 patients were included. Pooled all-cause mortality in intervention arm was 12.8% (95% confidence interval [CI]: 8.1%-17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR: 1.36; 95% CI: 0.97-1.89). Adverse events were also higher in HCQ subgroup (OR: 3.88; 95% CI: 1.60-9.45). There was no difference in other secondary outcomes. There is a need for well-designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
---|---|
Enthalten in: |
Journal of medical virology - 93(2021), 2 vom: 08. Feb., Seite 775-785 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Thoguluva Chandrasekar, Viveksandeep [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.01.2021 Date Revised 06.02.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/jmv.26302 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM312441592 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM312441592 | ||
003 | DE-627 | ||
005 | 20231225144425.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jmv.26302 |2 doi | |
028 | 5 | 2 | |a pubmed24n1041.xml |
035 | |a (DE-627)NLM312441592 | ||
035 | |a (NLM)32667699 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Thoguluva Chandrasekar, Viveksandeep |e verfasserin |4 aut | |
245 | 1 | 0 | |a Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.01.2021 | ||
500 | |a Date Revised 06.02.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 Wiley Periodicals LLC. | ||
520 | |a Treatment options for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on efficacy and safety profiles. We performed a systematic review and meta-analysis of studies on patients ≥18 years reporting data on therapeutic interventions in SARS-CoV-2. Primary outcome was all-cause mortality and secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge, and progression to severe disease. Pooled rates and odds ratios (OR) were calculated. Twenty-nine studies with 5207 patients were included. Pooled all-cause mortality in intervention arm was 12.8% (95% confidence interval [CI]: 8.1%-17.4%). Mortality was significantly higher for studies using hydroxychloroquine (HCQ) for intervention (OR: 1.36; 95% CI: 0.97-1.89). Adverse events were also higher in HCQ subgroup (OR: 3.88; 95% CI: 1.60-9.45). There was no difference in other secondary outcomes. There is a need for well-designed randomized clinical trials for further investigation of every therapeutic intervention for further insight into different therapeutic options | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a HCQ | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a hydroxychloroquine | |
650 | 4 | |a meta-analysis | |
650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Drug Combinations |2 NLM | |
650 | 7 | |a lopinavir-ritonavir drug combination |2 NLM | |
650 | 7 | |a Lopinavir |2 NLM | |
650 | 7 | |a 2494G1JF75 |2 NLM | |
650 | 7 | |a remdesivir |2 NLM | |
650 | 7 | |a 3QKI37EEHE |2 NLM | |
650 | 7 | |a Adenosine Monophosphate |2 NLM | |
650 | 7 | |a 415SHH325A |2 NLM | |
650 | 7 | |a Hydroxychloroquine |2 NLM | |
650 | 7 | |a 4QWG6N8QKH |2 NLM | |
650 | 7 | |a tocilizumab |2 NLM | |
650 | 7 | |a I031V2H011 |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
650 | 7 | |a Alanine |2 NLM | |
650 | 7 | |a OF5P57N2ZX |2 NLM | |
700 | 1 | |a Venkatesalu, Bhanuprasad |e verfasserin |4 aut | |
700 | 1 | |a Patel, Harsh K |e verfasserin |4 aut | |
700 | 1 | |a Spadaccini, Marco |e verfasserin |4 aut | |
700 | 1 | |a Manteuffel, Jacob |e verfasserin |4 aut | |
700 | 1 | |a Ramesh, Mayur |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 93(2021), 2 vom: 08. Feb., Seite 775-785 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
773 | 1 | 8 | |g volume:93 |g year:2021 |g number:2 |g day:08 |g month:02 |g pages:775-785 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.26302 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 93 |j 2021 |e 2 |b 08 |c 02 |h 775-785 |